In the context of screening, our study suggests that the additional value of HE4, CA72-4 and p53 autoantibodies to CA125 as a first line test in screening for ovarian cancer of postmenopausal women from the general population is limited. This evidence concerns the gene WFDC2 and ovarian carcinoma.